Pharmalucence Revenue and Competitors

Pharmalucence traces its roots to CIS-US, Inc., the U. S. subsidiary of CIS bio international, itself an asset of CEA headquartered in Paris, France. CIS-US was incorporated in 1985 to commercialize medical applications derived from isotopic technologies developed by its French ownership. In the late 1980’s, the company acquired a production facility in Bedford, MA, establishing itself as a U. S. manufacturer of radiopharmaceuticals and medical devices. Between 1999 and 2007, CIS-US passed through three ownership changes, culminating in an employee privatization.